ATE385789T1 - Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen - Google Patents

Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen

Info

Publication number
ATE385789T1
ATE385789T1 AT00978588T AT00978588T ATE385789T1 AT E385789 T1 ATE385789 T1 AT E385789T1 AT 00978588 T AT00978588 T AT 00978588T AT 00978588 T AT00978588 T AT 00978588T AT E385789 T1 ATE385789 T1 AT E385789T1
Authority
AT
Austria
Prior art keywords
aldosterone
prevention
treatment
pathogenic conditions
antagonist
Prior art date
Application number
AT00978588T
Other languages
English (en)
Inventor
Gordon Williams
John Funder
Susan Garthwaite
Barbara Roniker
Kenton Fedde
Ricardo Rocha
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE385789T1 publication Critical patent/ATE385789T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT00978588T 2000-06-13 2000-11-14 Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen ATE385789T1 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US21106400P 2000-06-13 2000-06-13
US21145900P 2000-06-13 2000-06-13
US21125300P 2000-06-13 2000-06-13
US21125000P 2000-06-13 2000-06-13
US21126400P 2000-06-13 2000-06-13
US21131100P 2000-06-13 2000-06-13
US21134000P 2000-06-13 2000-06-13
US21145100P 2000-06-13 2000-06-13
US22135800P 2000-07-27 2000-07-27
US22136400P 2000-07-27 2000-07-27
US23305600P 2000-09-14 2000-09-14

Publications (1)

Publication Number Publication Date
ATE385789T1 true ATE385789T1 (de) 2008-03-15

Family

ID=27582731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978588T ATE385789T1 (de) 2000-06-13 2000-11-14 Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen

Country Status (11)

Country Link
EP (1) EP1289507B1 (de)
JP (1) JP2004503495A (de)
KR (1) KR20030010716A (de)
CN (1) CN1236763C (de)
AR (2) AR029134A1 (de)
AT (1) ATE385789T1 (de)
AU (3) AU1604001A (de)
CA (1) CA2407699A1 (de)
MX (1) MXPA02012257A (de)
PE (2) PE20011341A1 (de)
WO (2) WO2001095893A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
EP1455795A1 (de) 2001-12-12 2004-09-15 Pharmacia Corporation Verfahren zur behandlung von augenerkrankungen mit einem epoxy-steroidalen aldosterone rezeptor antagonisten
MXPA04005803A (es) * 2001-12-13 2004-11-01 Pharmacia Corp Metodos para tratamiento o profilaxis de efectos patogenicos mediados por aldosterona en un sujeto utilizando un antagonista de aldosterona epoxi-esteroidal.
KR20040091141A (ko) * 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CA2495376A1 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
ES2338781T3 (es) * 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Uso de la drospirenona para el tratamiento de una hipertension.
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
DE102011012712A1 (de) * 2011-03-01 2012-09-06 Frank Lehmann-Horn Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion
US20230048130A1 (en) * 2020-01-21 2023-02-16 University Of Southern California Ketogenic fasting-mimicking diet to improve kidney function
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
JP2002529405A (ja) * 1998-11-06 2002-09-10 ジー・ディー・サール・アンド・カンパニー 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法

Also Published As

Publication number Publication date
PE20011341A1 (es) 2002-02-06
EP1289507B1 (de) 2008-02-13
AU2001216580A1 (en) 2001-12-24
KR20030010716A (ko) 2003-02-05
AU2001216040B2 (en) 2006-06-15
WO2001095892A1 (en) 2001-12-20
EP1289507A1 (de) 2003-03-12
CA2407699A1 (en) 2001-12-20
AR029134A1 (es) 2003-06-04
AU1604001A (en) 2001-12-24
WO2001095893A1 (en) 2001-12-20
PE20020173A1 (es) 2002-03-14
MXPA02012257A (es) 2005-04-19
CN1236763C (zh) 2006-01-18
AR029680A1 (es) 2003-07-10
CN1455667A (zh) 2003-11-12
HK1060065A1 (en) 2004-07-30
JP2004503495A (ja) 2004-02-05

Similar Documents

Publication Publication Date Title
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
ATE325808T1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
DE60114027D1 (de) Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE310537T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties